Cancer colorectalis PD-1 / PD-L1 curationis

Colonia cancer immunotherapy, cancer rectalis immunotherapy, cancer colorectalis immunotherapy, et cancer colorectalis PD-1 / PD-L1 curatio.

Seventeen years ago, the number of drugs available for advanced colorectal cancer was very limited. There were only a few chemotherapeutic drugs and almost no targeted drugs. With the development of genomic testing and sophisticated cancer drugs, patients diagnosed with stage IV colonia cancer have more and more treatment options. Some patients can achieve clinical cure, while others can obtain more targeted immunotherapy options through genetic testing, resulting in longer survival time. At present, the survival time of advanced colorectal cancer has increased from less than one year to 3 years, and 20% of patients can survive for 5 years or longer.

In MMXX, quod novum treatment options praesto sint et a colorectal cancer aegris? Quid pharmaca sunt veniens ad forum, in tardus notitia compilavit Global oncologist Network Imperatoris Medici, quem pro secundum.

Holistic belli medicamento curatio provectus pro colonia cancer

1. Primum-linea curatio

Curatio optiones cancer colorectales provectae includunt chemotherapy, iaculis et immunotherapia. Ante curationem probatio genetica perficienda est, quia medicus consilium tractandi in loco originalis laeionis, mutationis geneticae et detectionis biomarcae faciet.

In elit velit, multi-medicamento colorectal cancer plerumque compositum. Miscere et inserere nomine sancti Doctores secundum ad actu situ patientes estote. Plerumque adsuesco assuesco in combinatione initial vexillum ratio est ut sequitur:

1. FOLFOX (IV / V-Fluorouracil oxaliplatin +)

2. CAPEOX (Xeloda (Capecitabine) + Oxaliplatina)

FOLFIRI 3. (IV / V-Fluorouracil irinotecan +)

4. FOLFOXIRI (IV / V-Fluorouracil + + irinotecan oxaliplatin)

Haec genera sunt plerumque adsuesco assuesco in combinatione cum Avastin® (bevacizumab) ad amplio superessendam, maxime in sinistram treatment of colonia cancer.

Loquens de quibus nos quoque necesse est admonere quisque quod curatio consilium et deploratae colorectal cancer tumores occurrunt in sinistra parte (descendens colonia, sigmoides colon, rectum) et dextrum latus (ascending colon, transversus colonia, cecum) sunt omnino diversis, et non confundetur. Post diagnosis, curatio omnes necesse habuerit edisserere invenire perito consilio vel auctoritate.

The specific plan for the left half of RAS / RAF wild-type patients is as follows. The recommended plan for Class I (preferred): FOLFOX / FOLFIRI ± Cetuximab Class II recommended plan: FOLFOX / CapeOx / FOLFIRI ± Bevacizumab; FOLFOXIRI ± Bevacizumab anti-

In RAS specifica consilium ad ius dimidium / RAF ferox genus, ut aegris non sequitur. Quod ego consilium gradu commendatae (malebat) FOLFOX / CapeOx / ± FOLFIRI bevacizumab; FOLFOXIRI ± bevacizumab. Cum + FOLFIRI Avastin, FOLFOXIRI V-anno altiore salutem rate de + avastin aestimatur esse duplex. Suspendisse II classis regimen: FOLFOX / ± FOLFIRI cetuximab.

2.-linea secundi curatio

In prima acie, ut non cum chemotherapy utuntur bevacizumab combined. Si curatio est non effective, non enim potest mutare victus et chemotherapy utuntur bevacizumab permanere. Scilicet, est etiam alterum mutare potest targeted pro chemotherapy medicamento simul solo curandum est, ut abercept immutare vel ramucirumab.

3. Tertius-linea recta-terga et curatio

Electio primae lineae et secundae lineae medicamentorum bene pro cancro colorectali plerumque quaedam medicamenta chemotherapy respective signa et medicamenta iaculis. Incipiens a tertia-linea curationis est curatio dorsi. Tractationis posterioris institutum uti potest aliquibus medicamentis chemotherapeuticis oralibus, quae modo prodierunt, inclusa TAS-102, ac S-1 (tegio), rifafine, vel immunotherapy, ut pembrolizumab (MSI-H).

Progressiones enim a colorectal cancer Lorem precise targeted

In colorectal cancer curatio in MMXVII version of guidelines, nisi per suasiones ad geneticae temptationis KRAS involvere, NRAS, et dMMR MSI DVD-H, et tardus ad treatment guidelines in MMXX, ut scuta nova BRAF, HER2017, NTRK, etc., sunt Point includitur nuper, per geneticae temptationis, intelligere hypothetica magis notitia colorectal cancer, nos potest auxilium elit plus options invenire. In salutem rate de mediocris aegris plus quam III annorum, duxit ex quibus est ingens cura medicina proficere.

1. Quod enim a colorectal cancer aegris probata deberet Genes

Post diagnosis, medicum oportet ducere geneticae temptationis cuiusque patientes estote ad metastatic colorectal cancer (mCRC) quam primum determinare est subgroup de morbus, quia haec notitia potest praedicere deploratae et curatio sicut HER2 extollendam insinuat anti-EGFR curatio medicamento resistentia. De his genes sit probata!

MSI, BRAF, KRAS, NRAS, RAS, HER2, NTRK.

2. Targets et medicamina potest targeted currently esse tractata

VEGF: Bevacizumab, Apsip

VEGFR: ramucirumab, rigofinib ., fruquintinib

EGFR: cetuximab, panitumumab

PD-I / I-PDL, pamluzumab, nivolumab

CTLA-IV: Ipilimumab

BRAF: Vimofinil, Connefini

NTRK: Larotinib

A list of targeted pro colorectal cancer medicinae et immunotherapy quia probatus est et usque ad domum et foris:

Indicia enim a colorectal cancer medicinae targeted

Quod sint obscurae notae sint bevacizumab : metastatic colorectal cancer and advanced, metastatic or recurrent cellula parva non-pulmonis cancer.

Graves sunt et trastuzumab : HER2-positive metastatic breast cancer, HER2-positive early breast cancer, HER2-positive metastatic gastric ADENOCARCINOMA or gastroesophageal junction adenocarcinoma patients.

Graves sunt et Pertuzumab : This product is suitable for combination with trastuzumab and chemotherapy as an adjuvant treatment for patients with high-risk recurrence of HER2-positive early pectus cancer.

Quod sint obscurae notae sint Nivolumab : epidermal growth factor receptor (EGFR) gene mutation negative and anaplastic lymphoma kinase (ALK) negative, previous disease progression or intolerable locally advanced or metastatic after receiving platinum-based chemotherapy Adult patients with non-small cell lung cancer (NSCLC).

Quod sint obscurae notae sint regorafenib : de aegris cum metastatico colorectali carcinomate antea tractato. Durvalumab, Tremelimumab, Ipilimumab, et lapatini .
b, non est tamen paratum in Sinis.

Gene mutationem EGFR

Angiokeratoma Corporis incrementum factor (EGFR) occurs in circiter X% of colonia cancer, maxime in sinistram.

Cetuximab panitumumab sunt publice et probatus per FDA in MMIV et MMVI a curatio provectus pro colorectal cancer.

Medicamento nomen panitumumab (Vectibix)

Scopum, EGFR

Manufacturer: Amgen (extra)

Indicia: EGFR positivum a colorectal cancer, colorectal cancer KRAS negans

Medicamento nomen Cetuximab (Erbitux)

Scopum, EGFR

Manufacturer: Merck (extra)

Indications: advanced colorectal cancer, caput et collum cancer

BRAF gene mutationem V600E

7-10% of colonia cancer aegris portare BRAF V600E mutationem. BRAF V600E mutationem in mutationem est activum BRAF quae variae sunt et summa proportionem BRAF.

Orci habet unique proprietatibus,

Maxime apparet in iure colonia;

Proportio est dMMR alta XX% reaching;

Pauper et deploratae BRAF V600E mutationem;

Atypical translationem modus,

Cum aegris habent plerumque genes BRAF mutant pauperes deploratae, et anti-cancer medicinae novus precise in duplo salvos fuisse ostensum est.

Studium invenit FOLFOXIRI + bevacizumab facti sunt ut optimus treatment pro aegris cum BRAF mutationes.

Et NCCN guidelines suadeo pro version Orationes V2 MMXIX secundo, de recta curatio metastatic enim a colorectal cancer BRAF V2019E:

+ + Verofenib irinotecan cetuximab / panitumumab

+ + Dabarafenib Trametinib Cetuximab / Panitumumab

Encorafenib + Binimetinib + Cetux / Pan

The good news is that in the face of such a dangerous BRAF V600E mutant metastatic colorectal cancer, on April 8, 2020, Pfizer announced that the US FDA has approved Braftovi® (encorafenib, Cornefinil) and Erbitux® (cetuximab) , Cetuximab) combined drug regimen (Braftovi second drug regimen), used to treat patients with metastatic colorectal cancer (mCRC) carrying BRAF V600E mutation. These patients have already received one or two pre-treatments. This approval also makes the Braftovi second drug regimen the first targeted therapy approved by the FDA for patients with mCRC carrying BRAF mutations.

Gene mutationem Kras

Ferox genus, KRAS colonia cancer curatio est recta, primum quia de targeted combination chemotherapy arbitrium, ita quod genus chemotherapy est optio elige?

Dum eligens quaedam targeted medicamento, quod est eligere suadetur chemotherapy cum iam victus OS, hoc est, cetuximab debet compositae cum FOLFOX et debet compositae cum bevacizumab FOLFIRI. Et elegit de specifica consilium indiget sit propria orci combined per analysis:

Si spes medicina fere cetuximab Virus maluit cum eo secundum efficientiam proxime superiore cetuximab bevacizumab;

Quia provectus aegris cum morbo incurabili laborauerit, non potest esse in prima acie bevacizumab combined cum chemotherapy, sequitur cetuximab aut panitumumab.

Colonia cancer cum aegris metastatic probata deberet per mutationem status RAS inter KRAS et NRAS. Saltem status de Exon II KRAS debet determinari potest.

Si condiciones permittere, ut opus sit status mutationem NRAS et exon KRAS exon II declaratur.

Bevacizumab cum duobus medicamentis chemotherapy coniunctum efficere potest PFS (progressio mediana liberorum superstes) et OS (superfluus superstes) beneficia patientibus mutationum KRAS.

Nam cum aegris RAS mutationes, potest habere usum cetuximab negativa consectaria etiam circa efficacitatem altiore.

KRAS aegroti sunt mutationes et mutationibus ut NRAS cetuximab vel non uti panitumumab.

HER2 extollendam

Overexpression II% non est usque ad extollendam HER2 in VI% de patientibus proficiebat colorectal cancer aut metastatic.

Pertuzumab and trastuzumab combine with different HER2 domains to produce synergistic inhibition on tuberculum cellulis.

My Pathway is the first clinical study to explore the efficacy of Pertuzumab + Trastuzumab therapy in patients with HER2 amplified metastatic colorectal cancer (regardless of KRAS mutation status). This study shows that HER2 dual-targeted therapy-Pertuzumab + Trastuzumab is well tolerated, or may be used as a treatment plan for patients with HER2 amplified metastatic colorectal cancer. Early genetic testing to identify HER2 mutations and consider early use of HER2 Lorem targeted may benefit patients.

NTRK gene mutationem fusione

I ad de V% de aegris develop colonia cancer NTRK fusionem, et quod probatio NGS suadetur.

From January 23 to January 25, 2020, the American Society of Clinical Oncology Tumor gastro Symposium (ASCO-GI) specifically analyzed the clinical drug effects of patients with gastrointestinal tumors carrying NTRK fusion protein.

In test consequitur ostendit quod group fuit XLIII% altiore remissionem rate de gastrointestinal cancer et altiore remissionem rate of colonia cancer aegris est L%. Durationem responsionis valde diversa est de 43 menses ad plures menses, quam 50.

After a median follow-up period of 19 months, the median overall survival time was up to 33.4 months, nearly three years. The one-year overall survival rate (OS) is 69%. At the time of the data cutoff, four colon cancer patients and one pancreatic cancer patient were still alive and their condition did not deteriorate. And the safety and tolerability of larotinib is good. Most adverse reactions are grade 1 or 2.

A LXXV annos femina de metastatic colorectal cancer (CRC) Is est valde felix:

Colonia Prima erroris.

Peritonaei cancer.

Iecoris metastasis.

Entratinib 1600mg / m II sublatus viva voce semel in hebdomada semel in hebdomada diebus ad IV (id dies IV / III dies off) Tres autem iungit hebdomadas omnibus diebus XXVIII. Post octo weeks curatio est, quicquid laesum est signanter reducitur.

Colorectal cancer immunotherapy et novum breakthrough inventory

Pronostico ordo, et h Laptop MSI BRAF ferox genus> MSI DVD-H, BRAF mutant> mss ferox, et genus BRAF> mss BRAF et mutant.

1. MSI DVD-II / dMMR colorectal cancer metastatic

Microsatellite princeps coniurationis instituunt (MSI DVD-H) est bonum prognosticum elementum et BRAF mutationem in rate de L% MSI DVD-H colorectal cancer.

LAPIS inhibitors immune est an efficens treatment pro MSI DVD-H. In immune LAPIS inhibitors currently locum Laptop MSI cum aegris C-genus includit mCRC pembrolizumab, nivolumab et ipilimumab.

Nivolumab / Ipilimumab linea compositum primo ostendit operationem elit

A fronte-linea compositum nivolumab (Opdivo) et ipilimumab (Yervoy) est ostensum est fortis et DIUTURNUS orci beneficium in aegris cum metastatic colorectal cancer (mCRC), et eius isque microsatellite instabilitatem (MSI DVD-ii) / mismatch repair De defectu Intentionis (dMMR) -a FACP, Johann Heinrich Leonard, MD, dixit populo cum pauper deploratae historia.

In Phase II iudicium CHECKMATE-CXLII, in investigatores examinato a salute et efficacitati treatment nivolumab plus humilis-dose ipilimumab ut prius, linea ad cum aegris MSI DVD-II / dMMR mCRC (n = XLV). Prior colloquium results summitto ad MMXVIII ESMO ostendit quod altiore responsionem rate (Orr) de LX% quod XLV aegris, morbus control et erat LXXXIV% rate. Ad MMXIX ASCO Annual et orci update iudicii denuntiatione. Mediana sequi-usque ad tempus 142 menses, ratio est ad compositum per visum Orr investigator augendam ad LXIV% et LXXXIV% de aegris cum morbo imperium in hebdomades ≥45.

2. mss colorectal cancer

Novum breakthrough in codicibus saec colorectal cancer, regorafen
ib (Stivarga) + nivolumab

Patientes estote quoniam et apud microsatellite stabilization (MSS) morbo, accepit de aegris LIII [compositum Lorem] et responsionem rate de XL% magno effectum, qui est in hac parte inaudita de aegris parebant.

Qui sunt pertinax anti-VEGF Lorem notitia consilium may have a synergistic effectus ad PD-I infida transfugerent. Nunc, quod est primum in re sit Hosius: populari celebrem. E combinatione harum duarum treatment consilia vidimus valde infigo results. Ergo, per anti-combining VEGF strategies LAPIS in immune suppressione, aegris cum morbo mss erit salvos maiora beneficia.

articulus conclusioni

Pellentesque Lorem In era, patientes estote ad omnes series intercedat recesse est a colorectal cancer Laptop MSI deprehendatur, mutationem RAS et analysis de BRAF et HER2 praestare existimavit, et aliis gene NTRK deprehendatur quatenus fieri potest. Geneticae temptationis (NGS) voluntas includitur in examen vexillum large initial et maxime in aegris. Nunc domesticis aegris potest temptavit per Global oncologist Network.

Non vivet in maligno revolution colorectal cancer curatio. Triticum vulgare de quo haec cognovimus bene multus of colonia cancer curatio et quomodo ad transferendum eam in orci iudicia. Non erit ultra in futurum. Ut ad profectum tardus investigationis elit, et optimum consilium pro colorectal cancer, cancer solum summo periti foris sunt dives orci experientia domi. Colorectal cancer aegris potest applicare ad consultationem cum auctoritate periti per Global oncologist Network obtinere optimus treatment consilium.